Maximum quantity allowed is 999
请选择数量
CAS RN: 21829-25-4 | 產品號碼: N0528
Nifedipine
×
![]()
×
| 包裝 | 價格 | 同一天 | 2-3个工作日 |
|---|---|---|---|
| 10G |
NT$1,920
|
12 | ≥40 |
| 25G |
NT$3,520
|
33 | 13 |
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | N0528 |
| 純度/分析方法 | >98.0%(E)(HPLC) |
| 分子式 / 分子量 | C__1__7H__1__8N__2O__6 = 346.34 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件 | Room Temperature (Recommended in a cool and dark place, <15°C) |
| 應避免的情況 | Light Sensitive |
| CAS RN | 21829-25-4 |
| Reaxys-RN | 497773 |
| PubChem Substance ID | 87573853 |
| SDBS (AIST Spectral DB) | 9750 |
| Merck Index(14) | 6528 |
| MDL編號 | MFCD00057326 |
產品規格
| Appearance | Light yellow to Yellow to Orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(UV-vis method) | min. 98.0 % |
| Melting point | 172.0 to 175.0 °C |
| Solubility in Acetone | almost transparency |
| NMR | confirm to structure |
性質
| 熔點 | 174 °C |
| 溶解性（可溶於） | Chloroform, Acetone |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H302 : Harmful if swallowed. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P312 + P330 : IF SWALLOWED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. |
相關法規
| RTECS # | US7975000 |
運輸資料
| HS編碼* | 2933.39-000 |
Application
Type IV secretion system (T4SS) research
Reference
- Chemical Genetics Reveals Bacterial and Host Cell Functions Critical for Type IV Effector Translocation by Legionella pneumophila
Application
Nifedipine: A Short-Acting Dihydropyridine Calcium Antagonist
Nifedipine is a short-acting dihydropyridine calcium antagonist. It selectively inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle without altering serum calcium concentrations, and induces a relaxation of the muscle. Because of the dilation of resistance vessels, blood pressure falls. Nifedipine is almost completely metabolized by cytochrome P450 3A4 (CYP3A4) in the liver. Nifedipine is a poorly water soluble agent and rapidly metabolized resulting in decreased bioavailability, and then the short-acting can provide increased the risk of stroke et al. Therefore, nifedipine slow-release formulations have been developed. (The product is for research purpose only.)
References
- Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders
- Comparative pharmacology of calcium antagonists: nifedipine, verapamil [V0118] and diltiazem [D3662] (a review)
- Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine
- In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5
- Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris (a review)
- Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved high-performance liquid chromatographic methodology
Application
Photobase Generator
References
- S. Song, S. Yokoyama, S. Takahara, T. Yamaoka, Polym. Adv. Technol. 1998, 9, 326.
- S. Song, S. Takahara, T. Yamaoka, J. Photopolym. Sci. Technol. 1998, 11, 171.
考研文獻
文章/手冊
TCIMail
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。